Marco Meglio

The SINBAR EMG, percentage of RWA from mentalis tonic and any activity, and percentage of RWA from FDS phasic activity all correlated with both disease duration and levodopa-equivalent dose.

Solomon L Moshe, MD, and Elissa Yozawitz, MD, from Montefiore Medical Center, discussed ways of reducing misdiagnosis of neonatal seizures and the future work needed to be done in this space.

Just over half (53%) of patients treated with the amantadine extended-release agent had greater than 50% reduction in time spent ON with dyskinesia and just over a quarter (27%) of patients had greater than 75% reduction.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed the abundance of research from the Florida Stroke Registry presented at ISC 2021.

Dosing will be paused in the open-label extension study (GEN-EXTEND) of tominersen while data are carefully analyzed to inform next steps on this study.

If approved, daridorexant would become the first sleep medication to demonstrate an improvement in sleep and daytime functioning, while keeping a favorable safety profile in adult and elderly patients.

In the phase 3 ADVANCE trial, all active treatment arms of atogepant met their primary end point, and the 30-mg and 60-mg doses met all 6 secondary end points with statistical significance.

Patients treated with NurOwn showed a mean improvement from baseline of 10% in timed 25-foot walk and a 4.9% improvement from baseline on the 9-hole peg test dominant hand.

The PoNS device becomes the first and only medical device cleared in the US for short-term treatment of gait in patients with multiple sclerosis.

The triage software yielded a sensitivity and specificity of 59.7% and 91.5%, respectively, for all scans in a study including more than 1000.

Behavioral abnormalities, reported from 14 studies, highlighted autistic-like traits and attention and hyperactivity disorders, slightly improving with age in patients with Dravet syndrome.

An overview of the NeurologyLive tweet chat honoring Multiple Sclerosis Awareness Month, featuring highlighted contributions from the medical community.

P values showed evidence of statistical significance at the conventional P <.05 threshold for all assessed non-inferiority margins.

There was very good to excellent level of agreement between the instrumented insoles and the gold-standard reference system.

Join NeurologyLive and Barry Singer, MD, on Twitter to discuss a number of topics regarding multiple sclerosis education and where the disease research is headed.

The duo from Montefiore Medical Center discussed a variety of topics surrounding an effort to improve seizure diagnosis and classification in newborns.

Treatment adherence and preference were largely in favor of the mandibular advancement device compared to continuous positive airway pressure.

Black patients were 16% less likely and Asian patients were 30% less likely to be able to function independently compared to non-Hispanic white patients following endovascular treatment.

Assessment of forced vital capacity with treatment of enzyme replacement therapy generally showed some initial stability followed by slow progressive decline.

The findings were consistent with the established safety profile for eculizumab in other non-neurologic indications, according to study authors.

Black patients accounted for 27% of the patients in the COVID-19 CVD Registry but accounted for 31% of the ischemic stroke cases.

A greater proportion of patients identified by newborn screening achieved a greater than 4-point increase in CHOP-INTEND scores during the observation period compared to those clinically diagnosed.

The findings suggest the externally altered proprioceptive feedback in forced exercises may be increasing cortical engagement.

Most treatment-emergent adverse events were mild in severity across both studies, with no evidence of renal toxicity, cardiac signals, or deaths.

Treatment with tPA within 0 to 60 minutes of last known normal occurred for 33% of patients on mobile stroke units, compared to 3% who received standard management.

Scholar Rock noted that the topline results from the 52-week treatment period are expected to be announced in the second quarter of 2021.

The postdoctoral researcher at Columbia University detailed a number of topics regarding the impact concealing multiple sclerosis diagnosis can have on a patient.

At each timepoint, all assessed participants with 3 SMN2 copies and the majority with 2 SMN2 copies were identified by PASA as not being tube fed.

Alise Carlson, MD, a resident at Cleveland Clinic, discussed her presentation from ACTRIMS Forum 2021 on the misdiagnosis of adult-onset genetic leukodystrophies as multiple sclerosis.

Treatment with nusinersen demonstrated no clinically meaningful changes in vital signs or clinical laboratory parameters, including urine parameters, in those with spinal muscular atrophy.